Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months | GenomeWeb

By Turna Ray

Although Transgenomic reported a 22 percent drop in revenues for its pharmacogenomics services business in the first quarter of 2011, company officials believe that segment of its business will contribute significantly to earnings in the coming months as a number of newly signed genomic testing arrangements with pharmaceutical companies start to bring in money.

Transgenomic reported a 39 percent increase in overall sales to $7.5 million from $5.4 million in the first quarter of 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based approach to identify gene variants, and more.

Stat News profiles the Wellcome Trust's Jeremy Farrar.

France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.

A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.